UPDATE: JP Morgan Upgrades Biogen Seeing Upside to Shares

In a report published Thursday, JP Morgan analyst Geoff Meacham upgraded Biogen Idec Inc. BIIB from Neutral to Overweight and raised the price target from $300.00 to $375.00. Meacham emphasized that Biogen's pipeline opportunities and MS survey implies an upside to shares. The analyst commented, “With respect to the MS franchise, we conducted a survey of 50 neurologists that points to upside for Tecfidera. Indeed, we have also fine tuned our MS estimates and are above consensus for Tecfidera, which is the key near-term commercial driver.” Shares of Biogen Idec closed at $308.81. The stock is currently up 2 percent in Thursday's premarket trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsGeoff MeachamJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!